Cathie Wood ARK Investment Management
Cathie Wood is the founder, CEO, and CIO of ARK Investment Management, an investment firm known for its focus on “disruptive innovation”. She gained widespread attention for her bold market calls and high conviction in cutting-edge technologies such as electric vehicles, genomics, and blockchain. Under her guidance, ARK’s exchange-traded funds (ETFs) attracted substantial interest from both retail and institutional investors. Wood’s investment philosophy emphasizes research-driven analysis and long-term growth potential, positioning her as one of today’s most influential voices in the world of finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$103M |
| 2 |
Coinbase
COIN
|
+$77.6M |
| 3 |
Ginkgo Bioworks
DNA
|
+$40.4M |
| 4 |
Twilio
TWLO
|
+$33.2M |
| 5 |
Prime Medicine
PRME
|
+$29.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fate Therapeutics
FATE
|
+$140M |
| 2 |
NVIDIA
NVDA
|
+$126M |
| 3 |
Spotify
SPOT
|
+$62.8M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$62.2M |
| 5 |
SGFY
Signify Health, Inc.
SGFY
|
+$61.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.56% |
| 2 | Technology | 34.23% |
| 3 | Consumer Discretionary | 8.65% |
| 4 | Communication Services | 7.7% |
| 5 | Financials | 5.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FATH
151
DELISTED
Fathom Digital Manufacturing Corporation
FATH
| $2.07M | 0.02% |
78,541
+19,887
| +34% | +$868K |
|
|
ARNC
152
DELISTED
Arconic Corporation
ARNC
| $2.06M | 0.02% |
97,425
+19,110
| +24% | +$400K |
|
153
Cellebrite
CLBT
$2.77B
| $2.06M | 0.02% |
472,479
+48,280
| +11% | +$216K |
|
|
SPNS
154
DELISTED
Sapiens International
SPNS
| $2.04M | 0.02% |
110,356
+14,122
| +15% | +$266K |
|
155
WIX.com
WIX
$3.43B
| $2.03M | 0.02% |
26,485
-9,907
| -27% | -$800K |
|
156
Camtek
CAMT
$6.85B
| $2.01M | 0.02% |
91,512
+9,554
| +12% | +$221K |
|
157
Kaiser Aluminum
KALU
$2.52B
| $1.99M | 0.02% |
26,251
-3,257
| -11% | -$261K |
|
|
TARO
158
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $1.97M | 0.02% |
67,912
+6,625
| +11% | +$197K |
|
159
Ituran Location and Control
ITRN
$1.01B
| $1.95M | 0.02% |
92,257
-6,389
| -6% | -$146K |
|
160
AudioCodes
AUDC
$232M
| $1.93M | 0.02% |
108,132
+3,824
| +4% | +$73.4K |
|
161
Playtika
PLTK
$904M
| $1.87M | 0.02% |
220,252
+34,118
| +18% | +$316K |
|
162
Allot
ALLT
$366M
| $1.87M | 0.02% |
542,479
+111,558
| +26% | +$418K |
|
163
GE Aerospace
GE
$361B
| $1.86M | 0.02% |
45,663
-11,997
| -21% | -$590K |
|
164
Radware
RDWR
$1.17B
| $1.85M | 0.02% |
93,911
-14,019
| -13% | -$293K |
|
165
JFrog
FROG
$11.4B
| $1.84M | 0.02% |
86,201
-21,614
| -20% | -$491K |
|
|
CYBR
166
DELISTED
CyberArk
CYBR
| $1.82M | 0.02% |
14,030
-3,363
| -19% | -$486K |
|
167
UroGen Pharma
URGN
$2.29B
| $1.75M | 0.02% |
196,938
-84,763
| -30% | -$803K |
|
168
Compugen
CGEN
$248M
| $1.73M | 0.01% |
2,410,414
+1,252,930
| +108% | +$1.09M |
|
|
169
Spotify
SPOT
$110B
| $1.68M | 0.01% |
21,309
-778,982
| -97% | -$62.8M |
|
170
Nano X Imaging
NNOX
$67.6M
| $1.39M | 0.01% |
188,736
+8,258
| +5% | +$91.5K |
|
171
Sea Limited
SE
$72B
| $1.29M | 0.01% |
24,789
-243,697
| -91% | -$13.1M |
|
172
iShares Russell 1000 Growth ETF
IWF
$125B
| $505K | ﹤0.01% |
+9,424
| New | +$518K |
|
173
ARK Genomic Revolution ETF
ARKG
$1.94B
| $455K | ﹤0.01% |
16,134
+14,553
| +920% | +$462K |
|
|
VIVS
174
VivoSim Labs
VIVS
$3.83M
| $302K | ﹤0.01% |
17,859
-5,047
| -22% | -$101K |
|
175
DuPont de Nemours
DD
$18.7B
| $254K | ﹤0.01% |
2,945
-380
| -11% | -$30.4K |
|
Similar funds
Cathie Wood's Q4 2022 Portfolio in Review
As of Q4 2022, Cathie Wood held 255 positions worth $11.5B, down 20% from $14.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Cathie Wood withdrew a net $790M in Q4 2022, closing 23 positions and reducing 163 holdings. Its most notable exit was Signify Health, Inc., an estimated $61.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 38% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Cathie Wood opened a new position in Prime Medicine worth $30.5M.
- Cathie Wood's largest Q4 2022 buy was Prime Medicine: 1,639,984 shares worth $30.5M.
- Cathie Wood added most to Tesla in Q4 2022, an estimated $103M increase.
- Cathie Wood's biggest Q4 2022 reduction was Fate Therapeutics, cutting an estimated $140M.
- Cathie Wood fully exited Signify Health, Inc. in Q4 2022, selling an estimated $61.1M.
- Cathie Wood's ten largest holdings make up 46% of its $11.5B portfolio in Q4 2022.
- Cathie Wood opened 5 new positions and closed 23 in Q4 2022.
- Cathie Wood's portfolio value fell 20% quarter-over-quarter to $11.5B.
Based on ARK Investment Management's 13F filing for Q4 2022, filed 24 Jan 2023.